Filter Results:
(133)
Show Results For
- All HBS Web
(240)
- News (73)
- Research (133)
- Events (1)
- Multimedia (3)
- Faculty Publications (93)
Show Results For
- All HBS Web
(240)
- News (73)
- Research (133)
- Events (1)
- Multimedia (3)
- Faculty Publications (93)
Sort by
- 29 Oct 2006
- Research & Ideas
The History and Influence of Andy Grove
forth. If you were stapled to an idea that lost favor in Hungary, it was worth your life. "Put common sense on a pedestal," says Grove. Once again, the direct opposite of the "uncommon nonsense" epitomized by the "virtual" cheering at... View Details
- 26 Jun 2000
- Research & Ideas
What’s an Internet Business Model? Ask a Health Care Professional
out how to get into a clinical trial to try an experimental drug. For their part, physicians are often befuddled by difficult cases that don't respond to traditional therapies. And pharmaceutical companies,... View Details
- 07 Aug 2000
- Research & Ideas
The Business of Biotech
the anatomical—basis of the disease." Genzyme, which currently has drugs in clinical trials for melanoma and breast cancer, hopes to have its first products on the market as early as 2004. "I think... View Details
- 15 Jan 2018
- Research & Ideas
A Better Business Model for Fighting Cancer
providing incentives and protecting proprietary information as needed—then leveraging the latest in artificial intelligence and machine learning through entities such as GNS Healthcare and IBM’s Watson to find an answer. Clinical View Details
- 08 Dec 2003
- Research & Ideas
Why Europe Lags in Pharmaceuticals and Biotech
the preferred testing ground for Phase 1 clinical trials of new drugs, the benefits of massive R&D spending and economic throw-offs are being enjoyed elsewhere, primarily in the United States and in an... View Details
- 10 Oct 2017
- First Look
First Look at New Research and Ideas, October 10, 2017
information and updates through early 2016. Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/717504-PDF-ENG Harvard Business School Case 618-025 Adaptive Platform Trials: The Clinical Trial of... View Details
Keywords: Sean Silverthorne
- 09 Feb 2010
- First Look
First Look: Feb. 9
human patients. Doyle believes NovoCure has the potential to become an important company with a major new cancer therapy platform but must complete pivotal (Phase III) clinical trials and receive FDA... View Details
Keywords: Martha Lagace
- 10 Oct 2000
- Research & Ideas
Cross-Sector Collaboration: Lessons from the International Trachoma Initiative
same time internally, our marketing and clinical trials folks had been working with Joe and they came to us and said, 'We've got a great opportunity here, but we do the commercial side of things and we need... View Details
- 05 Nov 2009
- Research & Ideas
A Market for Human Cadavers in All but Name?
Cooper, Thomas A. LaVeist, and Neil R. Powe. 2004. "Whole Body Donation for Medical Science: A Population-Based Study." Clinical Anatomy 17:570-577. Clay, Megan, and Walter Block. 2002. "A Free Market for Human... View Details
- 17 Mar 2009
- First Look
First Look: March 17, 2009
planned to pursue an aggressive schedule, moving the firm's Alzheimer's and Parkinson's disease imaging compounds through clinical trials and into the market. This involved expanding the firm's facilities... View Details
Keywords: Martha Lagace
- 20 Sep 2011
- First Look
First Look: September 20
surprised to hear as he nurtured the intraoperative radiotherapy business inside his company's microsurgery unit. But he also didn't expect it to take 13 years to get to the end of an all-important clinical View Details
Keywords: Sean Silverthorne
- 10 Jan 2017
- First Look
First Look at New Research: January 10, 2017
complete its clinical trials with very little startup funding and a small staff when compared to its competitors. Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/315087-PDF-ENG Harvard Business... View Details
Keywords: Sean Silverthorne
- 27 Mar 2012
- First Look
First Look: March 27
years, PAREXEL has built a strong technology services business that is its key differentiator, although clinical trials remain its most lucrative segment. Additionally, PAREXEL, like others in the industry,... View Details
Keywords: Carmen Nobel
- 18 Dec 2018
- First Look
New Research and Ideas, December 18, 2018
firms face little competition, even after the end of formal periods of patent protection and market exclusivity. Additionally, the evolving technologies of drug development—in particular, the increasingly common use of auxiliary endpoints in View Details
Keywords: Dina Gerdeman
- 01 Nov 2016
- First Look
First Look - November 1, 2016
seeks to complete its clinical trials with very little startup funding and a small staff when compared to its competitors. Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/315045-PDF-ENG Harvard... View Details
Keywords: Sean Silverthorne
- 18 Aug 2011
- Lessons from the Classroom
Business Plan Contest: 15 Years of Building Better Entrepreneurs
cause of blindness. In October 2009 the company entered into licensing and purchase option agreements with Alcon, which is now taking Potentia's drug candidate through Clinical 2 trials with a to-market goal... View Details
- 13 Jan 2009
- First Look
First Look: January 13, 2009
persevered and thrived despite personal, social, and professional obstacles. Purchase this case: http://harvardbusinessonline.hbsp.harvard.edu/ b01/en/common/item_detail.jhtml?id=409057 A Managerial Perspective on Clinical View Details
Keywords: Martha Lagace
- 28 Apr 2009
- First Look
First Look: April 28, 2009
in the past and now influence clinical trials and participate in regulatory decision-making. Yet these developments are far from universal and are taking very different forms around the world. Building on... View Details
Keywords: Martha Lagace
- 04 Feb 2014
- First Look
First Look: February 4
that investors were increasingly supporting late stage research with higher probabilities of success, while funding for riskier early stage research was drying up. Should FasterCures raise money and direct it toward early stage breakthrough therapies? Another issue was... View Details
Keywords: Sean Silverthlorne
- 11 Nov 2014
- First Look
First Look: November 11
organizations, Kaplan and Haas identify five common mistakes when managers attempt to cut health care costs. The mistakes are triggered, primarily, by working from the line-item expense categories on P&Ls, rather than clinically based... View Details
Keywords: Sean Silverthorne